Skip to content

Optimisation of anaesthetic procedures during radical retropubic prostatectomy

Optimisation of anaesthetic procedures during radical retropubic prostatectomy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00004315
Enrollment
230
Registered
2012-09-17
Start date
2005-01-03
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61

Interventions

Group 1: Radical retropubic prostatectomy with extended pelvic lymphadenectomy in a 25-30° Trendelenburg position with general anesthesia combined with a thoracic peridural catheter Group 2: Radical r

Sponsors

Charité - Universitätsmedizin Berlin
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: - eligible for radical retropubic prostatectomy - age between 18 and 75 years - Charlson Comorbidity Score = 1 or ASA < III - written informed consent according to the declaration of Helsinki (Hongkong 1989) - operation by a highly experienced surgeon (e. g. 50 RPX, 30 OPs/year)

Exclusion criteria

Exclusion criteria: - substantial comorbidities - Charlson Comorbidity Score >1 or ASA >II - substantial comorbidities which should be operated within same narcosis (e. g. hemicolektomy) - clotting disorders - degeneration of the lumbar spine or other contraindications against the insertion of a thoracic peridural catheter - not able or not willing to sign the informed consent - known alcohol- or drug abuse - every other circumstance/ condition that makes the participation of the individual in the study inappropriate

Design outcomes

Primary

MeasureTime frame
To provide evidence that the insertion of a thoracic peridural catheter leads to a reduction of blood loss during radical retropubic prostatectomy. Measurements: 1. haemoglobin difference between the day before surgery and the first postoperative day; 2. intraoperative blood loss, assessed by a) volume of the surgical aspirator and b) weighing of the intraoperatively used surgical drapes; 3. daily measurement of the haemoglobin in the drainage secretion until removement of drainage; 4. haemoglobin one day before discharge (normally days 4-7).

Secondary

MeasureTime frame
- duration of the operation: Measurement in minutes from skin incision to skin suture - oncosurgical results: TNM status and R status according to histopathological findings with a focus on R1-resections in correlation to TNM status - duration of hospitalization: measurement in days - documentation of all undesirable side effects, especially: - thrombosis - pulmonary embolism - rectal injury - injury to nerves - acute renal failure - myocardial ischemia or infarction

Countries

Germany

Contacts

Public ContactDaniel Baumunk

Universitätsklinikum Magdeburg A. ö. R.

daniel.baumunk@med.ovgu.de00493916713337

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026